Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer [Pediatric Oncology]

Conclusion
Compared with doxorubicin, daunorubicin was less cardiotoxic among survivors of childhood cancer than most current guidelines suggest. This may have implications for follow-up guidelines. The feasibility of substitution of doxorubicin with daunorubicin in childhood cancer treatment protocols to reduce cardiotoxicity should be additionally investigated.

Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Feijen, Leisenring, Stratton, Ness, van der Pal, Caron, Armstrong, Green, Hudson, Oeffinger, Robison, Stovall, Kremer, Chow Tags: Long Term Survival & Late Effects Pediatric Oncology Source Type: research